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Background. Chikungunya virus (CHIKV) infection induces arthralgia. The involvement of inﬂammatory
cytokines and chemokines has been suggested, but very little is known about their secretion proﬁle in CHIKV-
infected patients.
Methods. A case-control longitudinal study was performed that involved 30 adult patients with laboratory-
conﬁrmed Chikungunya fever. Theirproﬁles of clinical disease, viral load, and immune mediators wereinvestigated.
Results. Whenpatientsweresegregatedintohighviralloadandlowviralloadgroupsduringtheacutephase,those
with high viremia had lymphopenia, lowerlevels ofmonocytes, neutrophilia, andsigns ofinﬂammation.The high viral
load group was also characterized by a higher production of pro-inﬂammatory cytokines, such as interferon-a and
interleukin (IL)–6, during the acute phase. As the disease progressed to the chronic phase, IL-17 became detectable.
However, persistent arthralgia was associated with higher levels of IL-6 and granulocyte macrophage colony-
stimulating factor, whereas patients who recovered fully had high levels of Eotaxin and hepatocyte growth factor.
Conclusions. The level of CHIKV viremia during the acute phase determined speciﬁc patterns of pro-
inﬂammatory cytokines, which were associated with disease severity. At the chronic phase, levels of IL-6, and
granulocyte macrophage colony-stimulating factor found to be associated with persistent arthralgia provide
a possible explanation for the etiology of arthralgia that plagues numerous CHIKV-infected patients.
Chikungunya fever (CHIKF) has emerged as an im-
portant infection in South-East Asia, the Indian Ocean
region, and Europe [1–6]. CHIKF is an acute illness
characterized by fever, rash, and arthralgia, with
occasional involvement of the nervous system and liver.
Incapacitating arthralgia has been reported to persist for
years in some patients [7–9]. The causative agent of
CHIKF, Chikungunya virus (CHIKV), is a linear single-
stranded, positive-sense RNA virus with a length
of 11.8 kb. It belongs to the Alphavirus genus in the
Togaviridae family and is known to induce prominent
joint pathologies [8, 9]. Of concern, re-emerging
CHIKVhasbeenassociatedwithconsiderablemorbidity
and some fatalities, whereas CHIKF was considered to
be relatively benign previously. Although clinical fea-
tures of acute CHIKV infection have been described
[10–12],little isknownabout its long-term sequelae and
the pathogenesis of arthropathy.
It has been proposed that CHIKV-induced
arthralgia has an immunopathologic origin [13–15]. It
has been suggested that interleukin (IL)–1b, IL-6, and
Received 20 May 2010; accepted 5 August 2010.
aA.C., Z.H. and E.K.S.O. contributed equally to this work.
Potential conflicts of interest: none reported.
Reprints or correspondence: Dr Lisa F.P. Ng, Laboratory of Chikungunya Virus
Immunity, Singapore Immunology Network, 8A Biomedical Grove, #04-06,
Immunos, Biopolis, Singapore 138648 (lisa_ng@immunol.a-star.edu.sg).
The Journal of Infectious Diseases 2011;203:149–157
 The Author 2011. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please e-mail:
journals.permissions@oup.com
This is an Open Access article distributed under the terms of the Creative Commons
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/
2.5), which permits unrestricted non-commercial use, distribution, and reproduction
in any medium, provided the original work is properly cited.
1537-6613/2011/2032-0001$15.00
DOI: 10.1093/infdis/jiq042
Chikungunya Pathology and Cytokines d JID 2011:203 (15 January) d 149RANTES are associated with disease severity in acutely in-
fected patients and that these markers can be used to identify
patients with poor prognosis for special monitoring [16].
Treatment for CHIKF is largely palliative and based primarily
on anti-inﬂammatory drugs [7]. Because of the prominent in-
volvement of the immune system and cytokines throughout the
acute and chronic disease phases, there is potential for the de-
velopment of therapeutic modulators against the immuno-
pathologic effects of CHIKV infection. We therefore conducted
this longitudinal study as a follow-up to an earlier report [16] to
further deﬁne circulating levels of immune mediators, from the
acute to convalescent and chronic phases of the infection, in 30
laboratory-conﬁrmed cases of CHIKF in Singapore.
MATERIALS AND METHODS
Ethical Approval
Written informed consent was obtained from all participants.
The study was approved by the National Healthcare Group’s
domain-speciﬁc ethics review board (DSRB Reference No. B/08/
026)
Patients and Plasma Collection
The study included 30 patients with CHIKF who were ad-
mitted to the Communicable Disease Centre at Tan Tock Seng
Hospital from 1 August through 23 September 23 2008. The
outbreak occurred in an industrial area where the source
population comprised predominantly male workers, with
only 4 female individuals among the 30 patients in this study.
Plasma specimens were collected at 4 times after illness onset:
(1) on the day of admission to the hospital (acute phase;
median, 4 days after illness onset), (2) on the day of discharge
from the hospital (early convalescent phase; median, 10 days
after illness onset), (3) 4–6 weeks after illness onset (late
convalescent phase), and (4) 2–3months after illness onset
(chronic phase). All patients were conﬁrmed to have CHIKF
by reverse-transcription polymerase chain reaction (RT-
PCR). Crossing-point values were used to derive viral loads
from a standard curve generated by 10-fold serial dilutions of
a1 310
8 plaque forming unit (pfu)/mL stock. Data on de-
mographic characteristics and premorbid conditions were
collected at hospital admission. Routine hematological, bio-
chemical laboratory test ﬁndings and CHIKV load were
monitored for the ﬁrst and second collections. Patients’
clinical features were evaluated at all 4 collection times. Illness
was deﬁned as severe if a patient had either a maximum tem-
perature .38.5
C, a maximum pulse rate .100 beats/min, or
a nadir platelet count ,100 3 10
9 cells/L [16]. Patients who do
not fulﬁll these criteria were classiﬁed as having mild illness. In
addition, plasma specimens were collected from 8 healthy vol-
unteers as controls. All plasma specimens collected werealiquoted
a n ds t o r e da t280
C until use.
Multiplex Microbead Immunoassay for Cytokine Quantification
Plasmatic cytokine levels were measured using the Biosource
Human Cytokine Assay Kit (Invitrogen) according to the
manufacturer’s instruction, as described elsewhere [16]. Results
were acquired using the Luminex 200 instrument (Millipore),
with IS 2.3 software, based on standard curves plotted through
a 5-parameter logistic curve setting.
Data Analysis
Continuous variables were compared among different disease
phases and patient groups with use of a nonparametric Mann–
Whitney U test (1-tailed) analysis. Patient group comparisons
included (1) patients with CHIKF and high viral load (HVL)
versus patients with CHIKF and low viral load (LVL), (2)
patients with CHIKF versus normal control subjects, and (3)
patients with CHIKF and persistent arthralgia versus patients
withCHIKF andfullrecovery.P values , .05 wereconsidered to
be statistically signiﬁcant. In addition, the relationships between
CHIKV load and cytokines and between C-reactive protein
(CRP) and cytokines were determined using Pearson’s correla-
tion analysis. Pearson’s correlation coefﬁcient (r) ..6 was
considered to be strong. Two-way hierarchical clustering was
done as described elsewhere [16].
RESULTS
Characteristics of Patients with CHIKV Infection
Of the 30 patients with CHIKF in the study, 26 were male and 4
were female; their enrollment from an industrial area, where the
outbreak occurred, explains the highmale-to-female ratio.Their
ages ranged from 23 to 67 years (mean, 39 years; median, 36.5
years) (Table 1). None had underlying medical conditions.
Slightly more than half (53.3%) had severe illness from CHIKV
infection, but the majority (25 of 30) recovered without any
remarkable symptoms. Arthralgia (60.0%), fever (46.7%), my-
algia (46.7%), and rash (43.3%) were the most common pre-
senting symptoms at hospital admission. Joint swelling occurred
in 4 patients; 3 had swelling of the ﬁngers, and 1 had both knee
and shoulder swelling. At hospital discharge, all joint swelling
had resolved. None of the 4 patients had persistent arthralgia. A
small proportion of patients continued to have rash (10%)
during the late convalescent phase (4–6 weeks after illness on-
set), which was resolved by the chronic phase (2–3 months after
illness onset). Arthralgia or joint pains persisted at the chronic
phase (month 2–3 after illness onset) in 4 other patients
(13.3%). Most laboratory parameters were unremarkable at the
time of hospital admission, except for CRP level; the mean peak
CRPlevelforthe 30patientswithCHIKFwas24.296 24.07mg/
dL (normal range, 0.0–5.0 mg/dL).
At hospital admission, viremia was observed in all except one
patient. The mean CHIKV load in viremic patients was 6.33 3
10
7 pfu/mL (range, 4.69 3 10
3–5.62 3 10
8 pfu/mL), well within
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of the patients continued to have detectable viral loads (range,
2.88 3 10
3–3.29 3 10
4 pfu/mL). On the basis of their viral loads
at admission to hospital, the 30 patients could be divided into 2
distinct groups: HVL group and LVL group (Figure 1A).
Thirteen (93%) of 14 patients with HVL (mean viral load,
1.31 3 10
8 pfu/mL; range, 1.42 3 10
5–5.63 3 10
8 pfu/mL)
presented with severe clinical illness, compared with only 3
(19%) 16 patients with LVL (mean viral load, 1.95 3 10
4 pfu/
mL; range, 1 3 10
2–5.36 3 10
4 pfu/mL) (Table 1, Figure 1A).
The magnitude of CRP level elevation in the HVL group
(median, 29.6; interquartile range [IQR], 21.8–41.5 mg/dL) was
signiﬁcantly greater, compared with that in the LVL group
(median, 7.8; IQR, 2–12.4 mg/dL; P , .001) (Figure 1B). More
pronounced lymphopenia was observed in the HVL group
during the acute phase, with a signiﬁcantly lower proportion of
lymphocytes (median, 10.3%; IQR 5.9%–13.5%), compared
with the LVL group (median, 27.4%; IQR, 15.2%–32.2%;
P , .01) (Figure 1C). After the acute phase of infection, lym-
phocyte counts in all patients were restored to normal levels by
the early convalescent phase (median, 26.6%; IQR, 21.6%–
31.1%). Lower levels of monocytes were also more pronounced
in the HVL group (median, 9.4%; IQR, 8.5%–11.4%), com-
pared with the LVL group (median, 13.0%; IQR, 8.4%–16.3%;
Table 1. Demographic and Epidemiologic Data for 30 Patients with Confirmed Chikungunya Virus (CHIKV) Infection
Patient (Sex,
Age in years)
Duration
of fever,
Days
Acute
illness
severity
a
CHIKV load,
pfu/mL
CRP level,
mg/dL
Lymphocytes,
%
Neutrophils,
%
Monocytes,
%
Clinical outcome
b
CHIKV 1 (M, 40) 3 Severe 5.62E108 77.9 5.9 84.2 8.7 Complete recovery
CHIKV 2 (M, 23) 8 Severe 3.45E108 93.7 5.8 84.0 9.6 Complete recovery
CHIKV 3 (M, 62) 7 Severe 3.45E108 46.7 13.6 73.8 10.2 Lethargy, weakness
CHIKV 4 (M, 43) 5 Severe 3.45E108 46.1 5.1 85.3 9.1 Complete recovery
CHIKV 5 (M, 29) 6 Severe 2.12E108 58.9 6.3 79.4 14.2 Complete recovery
CHIKV 6 (M, 35) 7 Severe 1.14E107 0.4 32.3 57.9 8.5 Complete recovery
CHIKV 7 (M, 30) 4 Severe 1.14E107 29.6 11.5 77.6 10.6 Complete recovery
CHIKV 8 (M, 35) 4 Severe 2.64E106 9.0 11.6 74.1 13.5 Complete recovery
CHIKV 9 (M, 26) 3 Severe 9.97E105 20.8 4.3 87.7 7.9 Complete recovery
CHIKV 10 (M, 28) 4 Severe 3.76E105 22.8 15.9 75.7 7.5 Complete recovery
CHIKV 11 (M, 49) 2 Severe 3.76E105 25.7 13.3 74.8 11.6 Complete recovery
CHIKV 12 (M, 50) 6 Severe 2.31E105 36.9 5.9 80.0 8.6 Complete recovery
CHIKV 13 (M, 38) 3 Severe 2.31E105 34.2 30.3 56.9 12.3 Complete recovery
CHIKV 14 (M, 60) 3 Mild 1.42E105 56.4 9.1 84.4 5.9 Complete recovery
CHIKV 15 (F, 62) 7 Severe 5.36E104 8.5 24.3 91.0 3.0 Complete recovery
CHIKV 16 (M, 45) 0 Mild 5.36E104 2.1 20 57.0 12.0 Complete recovery
CHIKV 17 (M, 34) 3 Mild 5.36E104 9.2 45.4 51.0 15.9 Complete recovery
CHIKV 18 (M, 29) 2 Severe 2.02E104 46.9 18.6 70.5 13.3 Persistent arthralgia
CHIKV 19 (F, 67) 7 Mild 2.02E104 10.7 6 68.0 19.0 Complete recovery
CHIKV 20 (M,24) 3 Mild 2.02E104 9.3 45.6 41.0 12.6 Complete recovery
CHIKV 21 (M, 34) 0 Mild 2.02E104 1.0 33.8 41.9 17.4 Complete recovery
CHIKV 22 (M, 28) 7 Mild 1.24E104 2.9 32.6 56.8 8.2 Complete recovery
CHIKV 23 (M, 42) 2 Mild 1.24E104 12.4 24.3 67.0 7.9 Complete recovery
CHIKV 24 (F, 40) 6 Mild 9.37E103 17.3 69.9 69.9 15.4 Persistent arthralgia
CHIKV 25 (F, 31) 6 Mild 7.64E103 32.5 11.7 81.8 6.0 Persistent arthralgia
CHIKV 26 (M, 46) 9 Mild 7.64E103 4.9 28.2 57.9 12.7 Complete recovery
CHIKV 27 (M, 26) 4 Mild 7.64E103 7.8 36.1 37.2 17.3 Persistent arthralgia
CHIKV 28 (M,28) 5 Severe 7.64E103 0.3 18 60.0 14.0 Complete recovery
CHIKV 29 (M, 47) 8 Mild 4.69E103 2.0 28 49.0 21.0 Complete recovery
CHIKV 30 (M, 39) 1 Mild BDL 1.8 30.2 49.3 8.5 Complete recovery
NOTE. BDL, below detection limit (1E 1 02 pfu/mL); CRP, C-reactive protein.
All patients do not have any pre-morbid conditions.
The 4 clinical parameters, CRP level (normal range, 0.0–5.0 mg/dL), lymphocyte percentage (normal range, 20%–45%), neutrophil percentage (normal range,
45%–75%), and monocyte percentage (normal range, 3%–10%), were determined at admission to the hospital at acute phase (median, 4 days after infection
onset).
a Severity was deﬁned as having a temperature .38.5
C, pulse rate .100 beats/min, or platelet count ,100 x 10
9 cells/L.
b Clinical outcome at chronic phase (2-3 months after infection onset).
Chikungunya Pathology and Cytokines d JID 2011:203 (15 January) d 151P , .05) (Figure 1D). Neutrophilia was observed in the HVL
group (median, 78.5%; IQR, 74.3%–84.2%), compared with the
LVL group (median, 57.5%; IQR, 49.2%–68.5%; P , .001)
(Figure 1E).
Immune Mediator Profile Over Time During CHIKV Infection
The levels of 7 cytokines (interferon [IFN]–c, IL-2, IL-5, IL-10,
IL-13, tumor necrosis factor–a, and vascular endotherial growth
factor) were below the detection limit in most patients across all
4 collections. For mediators that were detected in our patients,
we observed 4 patterns representing different kinetics of pro-
duction. The ﬁrst proﬁle revealed cytokines, cytokine-related
factors, and chemokines that peak at the acute phase (median, 4
days after illness onset) (Figure 2A) and represented the innate
immune response at infection. Levels of cytokines, such as IFN-
a, IL-1Ra, IL-6, IL-7, IL-8, IL-12, and IL-15, were signiﬁcantly
increased in patients with CHIKF, compared with control sub-
jects. The second proﬁle revealed mediators that peaked during
the early convalescent phase (median, 10 days after illness onset)
(Figure 2B). The cytokine proﬁle of this group was characterized
by an increased secretion of T cell cytokines/chemokines (IL-
2R), with a bias toward Th2 type factors (IL-4, Eotaxin). Other
factors, such as hepatocyte growth factor (HGF), FGF-basic,
granulocyte colony-stimulating factor, and chemokines MIG
and MIP-1a in patients with CHIKF were also above the median
values in control subjects. The third proﬁle represents mediators
(RANTES and EGF) that peaked at the late convalescent phase
(4–6 weeks after illness onset) (Figure 2C). Finally, the fourth
proﬁle revealed cytokines (IL-17) that were detected only during
the chronic phase (2–3 months after illness onset) (Figure 2D).
Acute Viral Load Influences Production of Immune Mediators
Qualitative analysis of the proﬁle of mediators in Figure 3 revealed
a clear difference between the HVL and the LVL groups, mainly
during the acute phase. We found that levels of inﬂammatory
mediators IFN-a,I L - 1 R a ,I L - 6 ,I L - 1 2 ,I L - 1 5 ,I P - 1 0 ,a n dM C P - 1
were signiﬁcantly higher in the HVL group than in the LVL group
(Figure 4). In addition, the duration of production of these me-
diators was shorter in the LVL group than in the HVL group.
A signiﬁcantly strong positive correlation was found between
CHIKV load and IP-10 (Pearson’s r 5 .69; P , .0001), MCP-1
(Pearson’s r 5 .78; P , .0010), IFN-a (Pearson’s r 5 .72;
P, .0001), IL-12 (Pearson’s r5 .72; P, .001), IL-1Ra (Pearson’s
r 5 .77; P , .0001), and IL-6 (Pearson’s r 5 .76; P , .001).
Markers Associated with Chronic Joint Pain
Four patients reported persistent arthralgia during the chronic
phase (2–3 months after illness onset). We compared the me-
diator proﬁles in these 4 patients with those in patients who had
fully recovered. Plasma levels of 2 cytokines (IL-6 and GM-CSF)
were signiﬁcantly higher in patients with persistent arthralgia
(P , .05) (Figure 5A) during this chronic phase, whereas che-
mokines Eotaxin and HGF were signiﬁcantly lower, compared
with individuals who had fully recovered (P , .05) (Figure 5B).
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Figure 1. Association of laboratory parameters with viral load. A, Patients were separated into 2 groups according to their viral load: high viral load
(HVL; n 5 14) and low viral load (LVL; n 5 16). Comparisons of C-reactive protein (B), lymphocyte (C), monocyte (D), and neutrophil (E) levels between HVL
and LVL groups. Data are presented as mean 6 standard error of the mean (SEM). *P ,.05; **P ,.01; ***P ,.001, Mann–Whitney U test, 1-tailed.
152 d JID 2011:203 (15 January) d Chow et al.DISCUSSION
Despite CHIKV being ﬁrst isolated in 1952, the mechanisms
leading to the prominent pathologies of arthralgia and arthritis
in CHIKV infection have not been well studied [13, 15]. It was
only recently that a role for cytokines has been proposed for the
severity observed during acute CHIKV infection, both in hu-
mans [16] and in a nonhuman primate model [19]. However, it
is still unknown whether cytokines and other mediators, such as
chemokines, are involved in chronic joint pathologies induced
by CHIKV infection.
In this study, longitudinal immune mediator proﬁles were
determined in patients with CHIKF with different clinical fea-
tures and viral loads. We ﬁrst observed that viral load decreased
after an intense but relatively short viremic phase, during which
patientsexperiencedfeverandtypicalclinicalfeaturesofCHIKF.
During this CHIKF outbreak in August 2008, patients were
observed to have viremia lasting a median of 6 days [20]. This
was comparable to the earlier local Chikungunya cohort, in
which40%continuedtohavedetectableviralloadsafterday5of
illness [6], and cohorts from the Indian Ocean region, in which
viral RNA–positive resultswere observed in 60%, 50%, and 40%
of individuals at day 5, 6, and 7 after illness onset, respectively
[17].
In our study, acute disease severity in patients was deﬁned at
admission by either maximum temperature .38.5
C, a maxi-
mum pulse rate .100 beats/min, or a nadir platelet count ,100
310
9 cells/L [14, 19]. More patients from the HVL group (95%)
had severe CHIKF illness than those in the LVL group (19%).
We next observed that patients with high viral loads had sig-
niﬁcantly more elevated CRP levels, lymphopenia, and lower
monocyte levelsduringthe acute phase.Ofinterest,neutrophilia
was also observed. This suggests that viremia drives disease
pathogenesis and the associated signs and symptoms of CHIKF
(Figure 1).
Figure 2. Kinetic profiles of immune mediator expression over time during Chikungunya virus (CHIKV) infection. A, Acute phase, median 4 days after
illness onset; B; Early convalescent phase, median 10 days after illness onset; C, Late convalescent phase, 4–6 weeks after illness onset; and D, chronic
phase, 2–3 months after illness onset. Comparisons between patients with CHIKF and normal healthy control subjects were analyzed using a 1-tailed
Mann–Whitney U test. Horizontal dotted lines represent median values for healthy control subjects. Samples from all 30 patients were analyzed for each
time. Data are presented as mean 6 standard error of the mean (SEM). (*P ,.05; **P ,.01; ***P ,.001).
Chikungunya Pathology and Cytokines d JID 2011:203 (15 January) d 153Differences in viral load between the different patients could
be attributed to host genetic factors controlling virus invasion
and replication. Such a phenomenon has been observed for
other viruses [21–23]. Further studies are needed to understand
this in CHIKV-host interactions. Another explanation is dif-
ferences in the innate immune response, because recent reports
have shown that a swift response of IFN-a, induced by CHIKV
infection in vitro and in vivo [14, 19, 24], could control CHIKV
replication efﬁciently [24].
In a previous study, a limited number of samples (n 5 10)
taken during the acute phase of CHIKF illness in an earlier
outbreak, showed a signiﬁcant increased production of several
inﬂammatory cytokines. However, because of the small cohort
size, only striking differences could be observed [16]. In the
present study, a larger cohort with longitudinal sampling al-
lowed us to further deﬁne markers that could be involved in
severe illness and at various phases of CHIKF disease course.
Four unique immune mediator proﬁles were observed on the
basis of kinetics of production that represented the different
phases of anti-CHIKV immune response. The ﬁrst proﬁle, de-
ﬁned by a rapid but short-lasting production of mediators, was
characteristic of an early antiviral innate immune response
(Figure 2A). A high viral load was associated with high levels of
cytokines, likely inﬂammatory responses involved in antiviral
defense. IFN-a levels were signiﬁcantly higher in the HVL group
than in the LVL group only during the acute viremic phase
(median, 4 days after illness onset). IFN-a was induced by the
infection [25], but its production levels depended on the viral
load, because it occurred earlier in the HVL group than in the
LVL group (Figure 4). In the LVL group, some patients had
higher levels of IFN-a only during the early convalescent phase
(median, 10 days after illness onset) (Figure 4), conﬁrming re-
cent ﬁndings obtained with a cohort from Reunion Island [14].
A certain threshold in viral load is required before IFN-a is
induced. Alternatively, it could be attributable to a delayed in-
nate immune response. This could perhaps explain the clinical
outcome of persistent arthralgia experienced by patients in the
LVL group (Table 1).
High levels of IL-15 and IL-12 were found to be signiﬁcantly
produced, compared with healthy control subjects, in the ﬁrst 2
proﬁles (Figure 2A and B). Both cytokines (together with IFN-a
and IL-7, for which levels were also increased) are cytokines
Figure 3. Patterns of acute phase immune mediators, shown by 2-way hierarchical clustering. Each colored cell in the 3 hit maps represents the
relative levels of expression of a particular cytokine in a patient. Green indicates low production, and red indicated high production. The first and second
hit maps from the left represent the qualitative cytokine expression profiles of patients in the high viral load (HVL) and low viral load (LVL) groups,
respectively. Different disease phases are illustrated: acute phase (median, 4 days after illness onset), early convalescent phase (median, 10 days after
illness onset), late convalescent phase (4–6 weeks after illness onset), and chronic phase (2–3 months after illness onset).
154 d JID 2011:203 (15 January) d Chow et al.known to activate natural killer (NK) cells [26]. NK cells have
been recently shown, in humans and nonhuman primates with
CHIKV infection, to increase in number early after infection
and, thus, may participate in early control of CHIKV [19, 27].
IL-12 is also important for the development of Th-1 cells that
have potent antiviral activities [28]. Other mediators in the ﬁrst
proﬁle are chemoattractants, such as IL-8, MCP-1, and IP-10,
which could mobilize immune cells, such as neutrophils and
monocytes [29, 30], allowing them to migrate to the skin or to
the lymph nodes—2 sites of early viral replication, as shown in
the nonhuman primate model of CHIKV infection [19].
As in our previous study [16], IL-6 was observed to be the
only pyretic detected during the acute phase of CHIKV in-
fection. It was induced only in the HVL group, in which the
majority of patients (80%) had high fever (temperature,
.38.5
C) (Figure 2A and 4). It is also known to be the major
inducer of acute phase proteins, such as CRP, in humans [31,
32]. Patients in the HVL group showed increased levels of CRP,
amarkerofsystemicinﬂammation[33,34].CRPlevelswerealso
found to be strongly correlated with IL-6 levels (Pearson’s
r 5 .70; P , .001). Previously, CRP levels were shown to be
elevated during the acute phase of CHIKV infection [35].
During the 2005–2006 CHIKF outbreaks in Reunion Island,
CRP levelsinhospitalizedpatientswithCHIKFwerefoundtobe
signiﬁcantly higher than those in nonhospitalized patients [36,
37]. CRP measurement is a routine biochemical test used in the
clinical management of patients who receive a diagnosis of in-
fection,becauseofitslowcostandreadyavailability.Ifnomeans
exist to assess viral loads, an elevated CRP level could be used as
a surrogate marker for high viral load in acutely ill patients with
CHIKF. This could help in the early identiﬁcation and close
monitoring of patients with CHIKF who are at risk of
severe illness. The high IL-6 levels, together with the increased
levels of IL-8 and granulocyte colony-stimulating factor, could
also explain the observed neutrophilia and part of the joint
pathologies during the acute phase, because these immune
mediators have been previously associated with rheumatoid
arthritis [38]. The second proﬁle represents mediators that peak
at the early convalescent phase (median, 10 days after illness
onset), representing mediators involved in both the innate im-
mune response and in the establishment of an antiviral T cell
response.
The third proﬁle represents factors detected during the late
convalescent phase (4–6weeks afterillness onset),with a distinct
increased in RANTES and EGF levels, indicating recovery from
thrombocytopenia,becausethesecytokinesareproducedmainly
byplatelets. Inthe chronic phase of the infection (fourth proﬁle)
at 2–3 months after illness onset, high levels of IL-17 were seen.
This cytokine has a role in bone tissue inﬂammation and de-
struction and has been implicated in the etiology of rheumatoid
arthritis. Of note, previous studies have proposed that, in pa-
tients with rheumatoid arthritis, neutrophilia drives production
ofIL-17,whichdestroysthe extracellularmatrixandcausesbone
resorption, further inducing IL-6 production [39]. This is con-
sistent with our data indicating that patients with persistent
arthralgia have higher levels of IL-6 and GM-CSF, whereas pa-
tients who recovered have normal levels.Recovered patients also
had increased levels of HGF, a hormone that facilitates cartilage
N F I α α
0 1
1 1
2 1
* * * *
* *
a R 1 - L I
3 1
4 1
5 1
* * *
*
* * *
6 - L I
6
7
8 *
*
2 1 - L I
9
0 1
* * *
* *
* * *
6
7
8
9
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
o
k
i
n
e
9
0 1
1 1
2 1
* *
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
o
k
i
n
2
3
4
5
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
o
k
i
n
e
]
7
8
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
o
k
i
n
e
5
4 n a i d e M
s y a d
0 1 n a i d e M
s y a d
8
0 1 n a i d e M
s y a d
4 n a i d e M
s y a d
1
0 1 n a i d e M
s y a d
4 n a i d e M
s y a d
6
4 n a i d e M
s y a d
0 1 n a i d e M
s y a d
C
8
9
0 1
* * *
* * *
*
5 1 - L I
*
2 1
3 1
4 1
5 1
* * *
* * *
* * *
* * *
* * *
0 1 - P I MC 1 - P
1 1
2 1
3 1
4 1
* * *
*
* *
*
* * *
5
6
7
4 n a i d e M
s y a d
0 1 n a i d e M
s y a d
t
o
k
i
n
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
7
8
9
0 1
1 1
4 n a i d e M
s a d
0 1 n a i d e M
s a d
o
k
i
n
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
t
o
7
8
9
0 1
4 n a i d e M 0 1 n a i d e M
*
y
t
o
k
i
n
e
]
 
p
g
/
m
l
L
o
g
2
 
[
C
y
s y a ds y a d a d ys a d ys s y a d s y a d
p u o r G d a o L l a r i V h g i H
G d L l i V L L w o i V a rl L a od G p u o r
Figure 4. Expression of inflammatory mediators during acute Chikungunya virus (CHIKV) infection. Levels of IFN-a, IL-1Ra, IL-6, IL-12, IL-15, IP-10, and
MCP-1 in infected patients were compared with those in healthy control subjects with use of the nonparametric, 1-tailed Mann–Whitney U test.
Horizontal dotted lines represent median values for healthy control subjects. Data are presented as mean 6 standard error of the mean (SEM). (*P ,.05;
**P ,.01; ***P ,.001). Different disease phases are illustrated: acute phase (median, 4 days after illness onset), early convalescent phase (median, 10
days after illness onset), late convalescent phase (4–6 weeks after illness onset), and chronic phase (2–3 months after illness onset).
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suggesting a local anti-inﬂammatory response.
Two of the 4 patients who had persistent arthralgia during the
chronic phase (2–3 months after infection onset) were female.
These female patients represented two-thirds (66.7%) of the
female study cohort who presented with arthralgia, compared
with2(13.3%) of15males.Itwasobservedinanotherstudythat
female patients (100%) were signiﬁcantly more likely than male
patients (26.5%) to have persistent arthralgia at week 6 of illness
[20]. Our study has shedsomelightonthepossiblepathogenesis
of arthropathy and arthralgia in patients with CHIKF. However,
more work is needed to understand the immunopathology of
joint swelling in CHIKV infection.
In conclusion, the immune mediator proﬁles observed
through this longitudinal study have provided a better un-
derstanding of CHIKF immunopathology. A positive link be-
tween CHIKV infection and cytokine induction was clearly seen
throughout different phases of the disease, with speciﬁc cyto-
kines being involved at different phases of the infection, cor-
roborating observations from a previous study [16]. There are
statistical limitations with this study, mainly in terms of power,
because of the small number of samples from each patient.
However, we believe that the use of sequential samples from the
same individual throughout the disease course adds strength to
our study. The discovery of speciﬁc immune mediators involved
in disease progression not only gives a better idea of possible
therapeutic interventions, but also provides plausible mecha-
nisms in the complex area of cytokine signaling that could ex-
plain the pathogenesis of CHIKF and other immune-mediated
diseases.
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